Category Archives: Ilan Azuelos

It is time to improve treatment options for rare lung diseases such as progressive fibrosing interstitial lung disease.

Improving Outcomes for ILD Patients

As a specialist in Interstitial Lung Disease (ILD) at the Meakins-Christie Laboratories, Ilan Azuelos, MD is an ardent promoter of improving outcomes for ILD patients. Treatment options for people with rare lung diseases, such as progressive fibrosing interstitial pulmonary fibrosis, may portend a life expectancy of between five and six and a half years after onset of symptoms. Dr. Azuelos knows that with research and education of the general public, this life expectancy can be improved.

“Ainsi, les personnes affligées de cette maladie seraient en mesure de passer plus de temps avec leur famille et de profiter au maximum de la vie.”

Ilan Azuelos, MD, MSc

Fortunately, programs have been initiated to address this area of medicine. MEDTEQ+, a pan-Canadian consortium for medical innovation, is bringing together industry leaders such as Boehringer Ingelheim Canada in partnership against PF-ILD. They aim to identify potential solutions to address the gaps in care for patients with IPD-PF, with the goal of accelerating access to treatments that delay the deterioration of lung function.

With the general public more aware of the symptoms of the onset of lung disease, patients could seek out treatment at an earlier stage. Increased funding for research would lead to a better understanding and the development of novel treatment options. Each would play an important role in a better, perhaps longer, life after diagnosis.

Read the following articles to learn more of the importance of improving education and treatment options for patients with ILD:

funding news for the Meakins-Christie Laboratories

Five CIHR Project Grants awarded!

Five CIHR Project grants were awarded to Meakins and RECRU members in the Fall 2019 competition. Congratulations to ALL!

Basil Petrof. Co-Applicant: Sabah Hussain. Title: Understanding the basis of diaphragmatic weakness in critical illness. Ranked 1st in the Respiratory System Peer Review Committee!

Maziar Divangahi. Title: Reprogramming HSCs to generate protective trained immunity against TB. Ranked 2nd in the Immunology & Transplantation Peer Review Committee!

Maziar Divangahi. Title: Targeting the eicosanoid/macrophage axis to enhance host defense against influenza virus infection.

Carolyn Baglole. Co-Principal Investigator: Ilan Azuelos. Co-Applicants: Andrea Benedetti, Imed Gallouzi. Title: Prognostic and Therapeutic Utility of Human Antigen R (HuR) in Fibrosis.

Faiz Ahmad Khan. Co-Principal Investigators: Glenda Sandy, Christopher Fletcher, Neil Andersson. Co-Applicants: Marie Rochette, Carmen Sicilia, Dick Menzies, Stephanie Law, Richard Long, Alison Doucet. Title: Community Health Workers in Tuberculosis Prevention & Care Services in Nunavik.